Company research
Pacira BioSciences, Inc.
CIK 1396814Updated Sep 24, 2026
SecurityPCRX · NASDAQ · equity
Name history
Pacira Pharmaceuticals, Inc. · through Apr 9, 2019PACIRA INC · through Nov 5, 2008Blue Acquisition Corp · through Apr 16, 2007
PCRX price & chart
Loading TradingView…
NASDAQ:PCRX on TradingView ↗About the company
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®°, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
In the news
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 ↗
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION ↗
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC ↗
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,264,917,000Source | 1,553,516,000Source | 1,574,386,000Source | 1,681,200,000Source |
| Property, Plant and Equipment, NetUSD | 140,690,000Source | 167,169,000Source | 173,927,000Source | 183,512,000Source |
| GoodwillUSD | 20,214,000Source | 0Source | 163,243,000Source | 163,243,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 368,100,000Source | 425,970,000Source | 483,258,000Source | 540,546,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 158,545,000Source | 276,774,000Source | 153,298,000Source | 104,139,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 124,069,000Source | 113,304,000Source | 105,556,000Source | 98,397,000Source |
| Inventory, NetUSD | 152,863,000Source | 125,282,000Source | 104,353,000Source | 96,063,000Source |
| Assets, CurrentUSD | 547,974,000Source | 745,130,000Source | 509,994,000Source | 498,334,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 32,618,000Source | 21,929,000Source | 21,504,000Source | 15,223,000Source |
| Operating Lease, Right-of-Use AssetUSD | 41,777,000Source | 49,222,000Source | 61,020,000Source | 70,877,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 571,806,000Source | 775,168,000Source | 704,256,000Source | 906,190,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 48,000Source | 47,000Source | 46,000Source | 46,000Source |
| Additional Paid in CapitalUSD | 1,064,623,000Source | 1,009,435,000Source | 976,633,000Source | 924,095,000Source |
| Retained Earnings (Accumulated Deficit)USD | -199,322,000Source | -206,356,000Source | -106,796,000Source | -148,751,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,327,000Source | 343,000Source | 247,000Source | -380,000Source |
| Stockholders' Equity Attributable to ParentUSD | 693,111,000Source | 778,348,000Source | 870,130,000Source | 775,010,000Source |
| Liabilities and EquityUSD | 1,264,917,000Source | 1,553,516,000Source | 1,574,386,000Source | 1,681,200,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 120,590,000Source | 309,920,000Source | 97,383,000Source | 147,774,000Source |
| Operating Lease, Liability, CurrentUSD | 9,839,000Source | 8,887,000Source | 8,801,000Source | 9,121,000Source |
| Accounts Payable, CurrentUSD | 15,150,000Source | 19,133,000Source | 15,698,000Source | 15,220,000Source |
| Operating Lease, Liability, NoncurrentUSD | 36,176,000Source | 44,645,000Source | 54,806,000Source | 64,802,000Source |
| Deferred Income Tax Liabilities, NetUSD | 4,213,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | 20,572,000Source | 16,817,000Source | 13,573,000Source | 9,669,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 95,601,000Source | 80,124,000Source | 64,243,000Source | 89,785,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 372,189,000Source | 585,321,000Source | 522,437,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 0Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 372,189,000Source | — | — | — |
| Short-term InvestmentsUSD | 79,879,000Source | 207,841,000Source | 125,283,000Source | 184,512,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 91,023,000Source | 78,785,000Source | 75,574,000Source | 91,501,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 57,502,000Source | 51,171,000Source | 47,895,000Source | 48,092,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 10,742,000Source | 7,748,000Source | 7,159,000Source | 2,079,000Source |
| Increase (Decrease) in InventoriesUSD | 27,567,000Source | 20,929,000Source | 8,290,000Source | -2,486,000Source |
| Increase (Decrease) in Accounts PayableUSD | -5,598,000Source | 3,084,000Source | 916,000Source | 6,272,000Source |
| Deferred Income Tax Expense (Benefit)USD | 6,477,000Source | 20,621,000Source | 15,615,000Source | -7,945,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 151,994,000Source | 189,389,000Source | 154,649,000Source | 145,274,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 16,702,000Source | — | 0Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 99,481,000Source | -83,276,000Source | 77,541,000Source | -225,185,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 15,333,000Source | 10,636,000Source | 15,161,000Source | 30,076,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 5,617,000Source | 491,000Source | 106,000Source | — |
| Payments for Repurchase of Common StockUSD | 148,328,000Source | 25,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -369,627,000Source | 17,363,000Source | -183,031,000Source | -401,528,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -118,229,000Source | 123,476,000Source | 49,159,000Source | -481,439,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 158,545,000Source | 276,774,000Source | 153,298,000Source | 104,139,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,235,000Source | 15,418,000Source | 27,635,000Source | 33,295,000Source |
| Income Taxes Paid, NetUSD | 9,013,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -77,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 57,502,000Source | 51,171,000Source | 47,895,000Source | 48,092,000Source |
| Amortization of Debt Issuance CostsUSD | 2,840,000Source | 3,130,000Source | 2,996,000Source | 4,400,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 2,997,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | 57,288,000Source | 57,288,000Source | 57,288,000Source | 57,288,000Source |
| DepreciationUSD | 33,700,000Source | 21,500,000Source | 18,300,000Source | 34,200,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | 11,000,000Source | 0Source | 0Source | 10,000,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | -193,000Source |
| Gain (Loss) on Termination of LeaseUSD | 0Source | -2,165,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -983,000Source | 7,518,000Source | -16,926,000Source | 0Source |
| GoodwillUSD | 20,214,000Source | 0Source | 163,243,000Source | 163,243,000Source |
| Goodwill, Impairment LossUSD | 0Source | 163,243,000Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 25,866,000Source | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 25,866,000Source | 0Source | 0Source | 26,134,000Source |
| Income Tax Expense (Benefit)USD | 9,840,000Source | 36,454,000Source | 19,746,000Source | -2,607,000Source |
| InterestExpenseNonoperatingUSD | 17,446,000Source | 16,569,000Source | — | — |
| Investment Income, InterestUSD | 22,732,000Source | 19,689,000Source | 11,444,000Source | 4,542,000Source |
| LitigationSettlementLossUSD | 7,000,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | 7,034,000Source | -99,560,000Source | 41,955,000Source | 15,909,000Source |
| Nonoperating Income (Expense)USD | -2,317,000Source | — | -25,974,000Source | -46,722,000Source |
| Other Nonoperating Income (Expense)USD | -6,620,000Source | -373,000Source | -186,000Source | -11,288,000Source |
| Proceeds from Stock Options ExercisedUSD | 502,000Source | 0Source | 1,939,000Source | 24,387,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 726,411,000Source | — | 674,978,000Source | 666,823,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 368,759,000Source | 294,099,000Source | 269,441,000Source | 254,516,000Source |
| Operating Income (Loss)USD | 19,191,000Source | -73,371,000Source | 87,675,000Source | 60,024,000Source |
| Other Nonoperating Income (Expense)USD | -6,620,000Source | -373,000Source | -186,000Source | -11,288,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 16,874,000Source | -63,106,000Source | 61,701,000Source | 13,302,000Source |
| Income Tax Expense (Benefit)USD | 9,840,000Source | 36,454,000Source | 19,746,000Source | -2,607,000Source |
| Net Income (Loss) Attributable to ParentUSD | 7,034,000Source | -99,560,000Source | 41,955,000Source | 15,909,000Source |
| Earnings Per Share, BasicUSD per share | 0.16Source | -2.15Source | 0.91Source | 0.35Source |
| Earnings Per Share, DilutedUSD per share | 0.16Source | -2.15Source | 0.89Source | 0.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,566,000Source | 46,245,000Source | 46,222,000Source | 45,521,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 45,042,000Source | 46,245,000Source | 51,979,000Source | 46,538,000Source |
| Interest Expense (non-operating)USD | 17,446,000Source | 16,569,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 57,288,000Source | 57,288,000Source | 57,288,000Source | 57,288,000Source |
| Business Combination, Acquisition Related CostsUSD | 2,895,000Source | — | — | — |
| Costs and ExpensesUSD | 707,220,000Source | — | 587,303,000Source | 606,799,000Source |
| Current Income Tax Expense (Benefit)USD | 3,363,000Source | 15,833,000Source | 4,131,000Source | 5,338,000Source |
| Goodwill, Impairment LossUSD | 0Source | 163,243,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 19,615,000Source | -65,325,000Source | 66,257,000Source | 21,068,000Source |
| Interest ExpenseUSD | — | — | 20,306,000Source | 39,976,000Source |
| Interest Expense, DebtUSD | 17,446,000Source | 16,569,000Source | 20,306,000Source | 39,976,000Source |
| Investment Income, InterestUSD | 22,732,000Source | 19,689,000Source | 11,444,000Source | 4,542,000Source |
| LitigationSettlementLossUSD | 7,000,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,317,000Source | — | -25,974,000Source | -46,722,000Source |
| Research and Development ExpenseUSD | 117,312,000Source | 81,577,000Source | 76,257,000Source | 84,797,000Source |
Filing attachments
sccrifsummer2025-ex991.htm · 8-K · 2025-07-10
EX-99.1 2 sccrifsummer2025-ex991.htm EX-99.1 Document Exhibit 99.1 On July 10, 2025, Pacira BioSciences, Inc. sent the following note to employees: Subject: Organizational Update Please take a moment to read the note below, sent on behalf of Frank D. Lee ++++++++++++ Dear Colleagues, I want to share some important news regarding organizational changes at our Science Center Campus. After very careful consideration, we have made the decision to decommission the 45-liter facility, which …
Read attachment ↗